ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2020

DOYLESTOWN, Pennsylvania, May 12, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, today announced net sales of $1.9 million for the three months ended March 31, 2020, compared to net sales of $2.3 million for the three months ended March 31, 2019.

The Company incurred a net loss for the three months ended March 31, 2020 of $809,000, or ($0.07) per share, compared to a net loss of $1.0 million or ($0.09) per share, for the three months ended March 31, 2019.

The financial results for the first quarter of 2020 compared to the first quarter of 2019 principally reflect the net effect of a decrease in net sales of $430,000 due to a decrease in demand of third party customer orders, offset by (i) a decrease in administrative costs of $206,000 due principally to a decrease in professional fees, (ii) a decrease in sales and marketing expenses of $96,000 as a consequence of a reduction in marketing initiatives and (iii) a decrease in research and development expenditures of $35,000.

In addition on May 4, 2020, the Company resolved the final pending claim against the Company’s escrow account with Mylan and as a result the remaining funds, totaling $4.8 million, were released from the escrow account to the Company on May 7, 2020.

About the Company

We are a manufacturing and marketing company with deep experience with OTC consumer healthcare products and dietary supplements. We are engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand.

In addition, the Company also continues to actively pursue acquisition opportunities for other companies, technologies and products inside and outside the consumer products industry. For more information visit us at

 Investor Contact

Ted Karkus, Chairman and CEO
ProPhase Labs, Inc.
(267) 880-1111

ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)

  For the Three Months Ended 
  March 31, 2020  March 31, 2019 
Net sales $1,888  $2,318 
Cost of sales $1,473  $1,798 
Gross profit  415   520 
Operating expenses:        
Sales and marketing  170   266 
Administration  998   1,204 
Research and development  59   94 
Total operating expenses  1,227   1,564 
Loss from operations  (812)  (1,044)
Interest income, net  3   31 
Net loss $(809) $(1,013)
Other comprehensive income:        
Unrealized gain on marketable debt securities  11   15 
Total comprehensive loss $(798) $(998)
Basic and diluted loss per share: $(0.07) $(0.09)
Weighted average common shares outstanding:        
Basic and diluted  11,582   11,557 

ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)

  March 31, 2020  December 31, 2019 
Cash and cash equivalents $697  $434 
Marketable debt securities, available for sale $840  $926 
Accounts receivable, net $1,213  $2,010 
Inventory $1,703  $1,459 
Total current assets $9,505  $9,945 
Total assets $11,868  $12,274 
Total current liabilities $1,125  $933 
Total non-current liabilities $112  $110 
Total stockholders' equity $10,631  $11,231 

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.